Talcum Powder Lawsuit Updates

By David Meldofsky, California-licensed attorney

Last updated: September 9, 2026

Johnson & Johnson tried three times to settle the ovarian cancer talc claims through bankruptcy, and courts rejected all three. In July 2026 the company announced a settlement of roughly $5.5 billion instead, negotiated in the ordinary court system. This page covers where that stands, who it covers, and who it leaves out.

The Talc Litigation at a Glance

• Federal case group: MDL 2738, U.S. District Court for the District of New Jersey, before Judge Michael A. Shipp.
• Pending federal cases: 69,250, as of the September 1, 2026 federal court count. Thousands more sit in state courts.
• Settlement announced: late July 2026, a reported $5.5 billion.
• What it covers: ovarian cancer claims already on file in state and federal court, reported at roughly 76,000 claims across both systems.
• What it does not reach: mesothelioma claims, claims outside the United States, and claims nobody has filed yet.
• Condition: the lead plaintiff firms in the state and federal talc cases have to participate, representing at least 95 percent of the remaining claims, per J&J's own SEC filing.
• Status: announced, not final. No per-claim payment figures have been published.
• Deadlines: set by state law and normally tied to the diagnosis date. The settlement does nothing to them.

Where the Talc Litigation Stands Now

The federal talc cases are grouped together before one judge in New Jersey, Judge Michael A. Shipp, in what the courts call MDL 2738. Reported counts put it at 69,250 pending cases as of September 1, 2026, up from about 68,900 in early August and roughly 68,000 in June. It has been the largest active group of federal cases of its kind for some time, and it kept growing even as the settlement was announced.

You will see two different numbers in news coverage, and they are counting different things. The roughly 69,000 figure is the federal group alone, taken from the monthly report the federal courts publish on pending case groups. The roughly 76,000 figure that appears in settlement coverage is J&J's own count of the ovarian cancer claims it says the deal reaches, and that one spans state courts as well as the federal group. Neither number is wrong. They just have different edges.

Thousands of additional cases sit in state courts, which matters more here than in most mass torts because the biggest verdicts have come from state juries rather than the MDL. For the underlying allegations see Talcum Powder Ovarian Cancer Lawsuit, and for the asbestos contamination question see Which Talcum Powder Brands Have Faced Asbestos Concerns?

The July 2026 Settlement, and What It Covers

On July 27, 2026, Johnson & Johnson agreed to pay a reported $5.5 billion to settle the ovarian cancer talc claims. The company's filing with the SEC says the first payment will be no more than $3 billion in 2027, with nothing further due before 2028. The deal covers most of the remaining ovarian cancer claims in both state and federal court.

Does it cover you?

Before the specifics, one thing to be clear about. J&J is settling while continuing to say its talc is safe, contains no asbestos, and causes no cancer. The company's announcement calls the litigation meritless and frames the deal as a way to end the expense of fighting it. A settlement here is the end of a fight, not an admission.

If you have an ovarian cancer claim already filed, most likely yes. Three groups sit outside it. Mesothelioma claims are on a separate track. Cases outside the United States are unaffected. And the deal reaches claims that already exist, so a person who has not filed is outside it and stays outside it, whatever their diagnosis. This is one of the sharpest breaks from the bankruptcy plans J&J tried before, which were built to sweep in future claims as well.

The deal turns on a 95 percent vote

J&J's own filing with the SEC puts the condition at 95 percent, described there as "the express participation of at least of 95% of the remaining claims". The press release attached to that filing is more specific. It says the lead plaintiff firms across the state and federal talc cases have to participate, and that those firms together have to represent at least 95 percent of what is left on file.

That distinction matters if you have a claim. Some news coverage has described the threshold as 95 percent of claimants accepting the deal. The company's own wording puts the participation decision with the firms leading the litigation, on behalf of the claims they represent. If you have a lawyer in this litigation, that firm's position is the one that counts toward the threshold, and your own lawyer is the person who can tell you where your case sits.

The company paying is Johnson & Johnson

J&J spun its consumer health business off as Kenvue in August 2023, and stopped selling talc-based Johnson's Baby Powder worldwide the same year. The talc liability stayed behind. J&J's announcement says it kept the talc-related liabilities and agreed to cover Kenvue for costs from litigation in the United States and Canada. So a claim about a product that carried the Johnson's name runs at Johnson & Johnson, whatever the label says today.

How payments would be set

Payments are described as being set by a tiered grid based on objective features of each claim, and plaintiffs' counsel have said the fund is uncapped rather than a fixed pot divided among everyone. What has not been published is the grid itself. No per-claim figures are public, so anyone quoting you a number for your own case is estimating, not quoting the settlement.

One more thing about how this came about. J&J tried three times to cap its talc liability by putting a subsidiary into bankruptcy. Courts rejected all three, the last in 2025. That is why this settlement had to be negotiated in ordinary court, and it is why it can be turned down by claimants rather than imposed on them.

What has happened recently

• July 27, 2026, the settlement was announced. J&J agreed to pay a reported $5.5 billion to resolve the ovarian cancer claims. Reporting put the number of claims covered at around 76,000, across both state and federal courts, and described that as very nearly all of what is left on file. It only takes effect if enough claimants agree to it.
• July 22, 2026, the court asked for proof on causation. The MDL court ordered plaintiffs to show why the remaining talc claims should not be dismissed for inability to prove that talc caused any particular claimant's cancer. The order came after plaintiffs withdrew their experts on that question in two test cases, following a hearing on whether those opinions rested on reliable science. The settlement was announced five days later, which is why a deal and a dismissal threat were live in the same week.
• Through mid-2026, state court verdicts went both ways. A Minnesota court left a $65.5 million mesothelioma verdict standing, and a Los Angeles jury awarded $32 million in a death from pleural mesothelioma. In the same stretch another California jury found for J&J in an ovarian cancer case, and a Los Angeles judge threw out a $950 million punishment award while leaving the rest of that verdict in place.
• Earlier in 2026, the judge ordered both sides into mediation. He appointed an experienced mediator and required both sides to send people who could actually agree to a deal. That ran through the first half of the year and led to the July announcement.
• 2025, the third bankruptcy attempt failed. A bankruptcy court rejected J&J's plan, ending its third try at capping talc liability by putting a subsidiary into bankruptcy. That is why the 2026 settlement had to be negotiated in the ordinary court system instead.

Mesothelioma Talc Claims Run on Their Own Track

Talc litigation has always had two sides, and they are proven in different ways.

Ovarian cancer claims are about long-term use of talc powder. Mesothelioma claims are about asbestos found in the talc itself, and they are proven the way any asbestos case is: where and when someone was exposed, which product it was, and what the pathology shows.

The mesothelioma side is also further along. In the same announcement, J&J said it had already settled roughly 95 percent of the mesothelioma lawsuits on file, along with all state consumer protection claims and all disputes with its talc suppliers. Those were handled separately and earlier, on their own terms.

That is why the July settlement is described as an ovarian cancer settlement. If you have a mesothelioma diagnosis connected to talc, your claim sits with the wider asbestos litigation rather than inside this settlement. See Mesothelioma Lawsuit and Asbestos Exposure Lawsuits.

Your Filing Deadline Runs on Its Own Clock

This is the part worth acting on. Filing deadlines for talc claims are set by state law and are usually tied to the date of diagnosis. A settlement being announced does not pause them, extend them, or protect anyone who has not filed. If a diagnosis is recent, timing is normally the first thing a lawyer looks at.

What to watch from here

• Whether enough claimants accept the deal for it to take effect.
• How payments would be divided up and on what schedule.
• What happens to people who do not join it.
• Whether new filings slow down. They had not as of the September 1, 2026 count.
• How the federal court rules on the causation evidence it asked for.
• State court mesothelioma verdicts, which sit outside the settlement entirely.

How This Updates Page Fits With the Main Talc Page

The main Talcum Powder Ovarian Cancer Lawsuit page covers who the litigation involves, what is alleged, and how claims are evaluated. That material changes slowly. This page tracks docket movement and settlement status, which change often. Background on the science sits on Is Talcum Powder Safe? and Which Talcum Powder Brands Have Faced Asbestos Concerns?

Case counts, settlement terms, and court schedules reported here reflect what was public on the date above. The primary documents behind them are listed in Sources below.

Sources

• Johnson & Johnson, Form 8-K filed July 27, 2026 (SEC EDGAR) — the $5.5 billion commitment, the 95 percent participation condition, and the payment schedule of no more than $3 billion in 2027 with nothing further due before 2028.
• Johnson & Johnson, press release of July 27, 2026 (Exhibit 99.1 to the Form 8-K) — the July 22 causation order, the withdrawal of the plaintiffs' experts in two test cases, the participation requirement for the lead plaintiff firms, the earlier mesothelioma and consumer protection settlements, and the company's position that its talc is safe.
• Judicial Panel on Multidistrict Litigation, Pending MDLs — the monthly report the pending case count for MDL 2738 comes from, posted on the first business day of each month.
• U.S. District Court for the District of New Jersey, Johnson & Johnson Talcum Powder Litigation — the court hearing the federal cases, with the master docket number and the judges assigned to it.
• District of New Jersey, J&J Talcum Powder Orders — the court's own repository of orders issued in the litigation.
• govinfo, published opinions in 3:16-md-02738 (D.N.J.) — the written rulings in the case, including the decisions on expert testimony that the causation fight runs through.

Figures and dates above should be confirmed against the original sources.

Related Lawsuit Topics

About the Author

David Meldofsky is a California-licensed attorney and the founder of Lawsuit Informer, an educational platform focused on helping people understand lawsuits, consumer safety issues, and legal rights related to defective products and toxic exposures.

Learn more about our Editorial Policy or Contact us.

Last Updated: September 9, 2026

Educational information only. Not legal advice. No attorney-client relationship is formed.